DARWIN EU® - Incidence and characterisation of polyendocrine metabolic ovarian syndrome in Europe

19/08/2026
19/08/2026
EU PAS number:
EUPAS1000001090
Study
Ongoing
Subscribe
Download as PDF
Study summary
No information provided.
Study identification

EU PAS number

EUPAS1000001090

Study ID

1000001090

Official title and acronym

DARWIN EU® - Incidence and characterisation of polyendocrine metabolic ovarian syndrome in Europe

DARWIN EU® study

Yes

Study countries

Denmark
Finland
Netherlands
Spain
United Kingdom

Study description

Polyendocrine metabolic ovarian syndrome (PMOS), previously named polycystic ovary syndrome (PCOS), is a common, heterogeneous endocrine disorder affecting females. PMOS is characterised by substantial heterogeneity in its clinical presentation, diagnosis, and management across healthcare settings. A clear understanding of real-world pharmacologic management is needed to characterise how PMOS is treated in routine clinical practice. However, analyses describing the use of pharmacological therapies following PMOS diagnosis and Real-World Evidence on the incidence of various health outcomes among individuals with PMOS remain limited.

Study status

Ongoing
Research institutions and networks

Institutions

Networks

Contact details

Anna Saura-Lazaro

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned:
Actual:

Study start date

Planned:
Actual:

Date of final study report

Planned:
Sources of funding
EMA
Regulatory

Was the study required by a regulatory body?

Yes

Is the study required by a Risk Management Plan (RMP)?

Not applicable